By Colin Kellaher
Shares of Apnimed moved higher in their trading debut Friday after the clinical-stage pharmaceutical company's upsized initial public offering was priced at the high end of expectations.
The Cambridge, Mass., company sold 12 million shares at $16 apiece in the IPO, raising $192 million, after previously saying it planned to offer 10 million shares at between $14 and $16 each.
Apnimed shares were recently changing hands at $17.38, up 8.6%, after opening at $22.00.
Write to Colin Kellaher at colin.kellaher@wsj.com